Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Study of Soy Isoflavones (SOYA) Responder Analysis Among Patients Who Have 4G4G/4G5G Serine Protease Inhibitor Family E Member 1 (SERPINE1) Genotypes
Fowler, John R. , Cardet, J.C., Mhaskar, Rahul , Baptist, Alan P. , Dixon, Anne E. , Hanania, N.A., Israel, Elliot , Garrow, O.J., Moy, James N., Riley, Isaretta , Wang, J.G., Fowler, J., Nguyen, D.T., Casale, Thomas B. , Chiarella, Sergio E. , Garrow, Olivia Johnson, Nyenhuis, Sharmilee Maria , Smith, Lewis J. , Wu, Timothy , Cho, Seong , Kumar, Rajesh

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1344-A1344

10.1164/ajrccm.2025.211.abstracts.a1344 Get It

Abstract RATIONALE: 4G4G/4G5G SERPINE1 genotypes produce high concentrations of plasminogen activator inhibitor-1 and are associated with worse asthma outcomes. A secondary analysis of the American Lung Association (ALA) SOYA trial showed that soy isoflavones significantly reduced asthma exacerbations versus placebo among patients with 4G4G/4G5G SERPINE1 genotypes. We hypothesized that baseline characteristics predict optimal responders to soy isoflavones among this subgroup. METHODS: ALA-SOYA was a randomized controlled trial that tested the efficacy of soy isoflavones vs. placebo for reducing asthma exacerbations among adolescents and adults with symptomatic asthma. In this responder analysis among participants with 4G4G/4G5G SERPINE1 genotypes, baseline demographic and clinical characteristics were tested for effect modification of the treatment assignment (soy/placebo) on the primary outcome of annualized number of asthma exacerbations using interaction terms in negative binomial regression models, with a significance threshold of p-interaction=0.15. RESULTS: Data were available for n=168 participants. Soy reduced the annualized number of asthma exacerbations relative to placebo among patients with 4G4G/4G5G SERPINE1 genotypes (incident rate ratio (IRR)=0.37, 95% confidence interval (CI): 0.15-0.90, p=0.028). Self-reported adherence to baseline controller therapy was the only significant effect modifier of this association (interaction p=0.115), with those using inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) controller therapy at least twice weekly experiencing reductions in asthma exacerbations with soy versus placebo (IRR = 0.25, 95% CI: 0.09-0.69; p= 0.007) but not among those using ICS/LABA controller therapy less frequently (IRR = 1.33, 95% CI: 0.22-8.02; p= 0.757). CONCLUSION: Soy isoflavones reduce asthma exacerbations among patients with the 4G4G/4G5G SERPINE1 genotypes and are most effective in those with greater adherence to asthma controller therapy regimens.
Sirolimus Use During Pregnancy in Women With Lymphangioleiomyomatosis
Krishna, R. Vijay , Baqir, Misbah , Girod, C, Krishna, R., Johnson, Simon R. , Ataya, Ali , Baldi, Bruno Guedes , Diesler, Rémi , Henske, Elizabeth P. , Xu, Kai‐Feng , Gupta, Nishant

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1135-A1135

10.1164/ajrccm.2025.211.abstracts.a1135 Get It

Abstract Background: Lymphangioleiomyomatosis (LAM) is a rare, female-predominant, low-grade neoplasm that can lead to progressive diffuse cystic lung disease. Pregnancy has been associated with accelerated disease progression and increased risk of spontaneous pneumothoraces in women with LAM. Sirolimus is the current first line treatment for LAM and has demonstrated benefit in stabilizing lung function decline and reducing the risk of spontaneous pneumothoraces; however, there is unclear evidence regarding the risk benefit ratio of the use of sirolimus during pregnancy. Methods: We queried physicians across the LAM Clinic Network and obtained information regarding demographics, baseline characteristics, LAM related complications, lung function, sirolimus dosing, and pregnancy outcomes in women with LAM who took sirolimus during pregnancy. Results: We identified 9 women with LAM who had used sirolimus during pregnancy for a total of 12 pregnancies. All women had sporadic LAM with moderate lung function impairment prior to pregnancy: median FEV1 56% predicted, median DLCO 43% predicted, and 2 patients on supplemental oxygen. Sirolimus was used throughout pregnancy in most instances (10/12 (83.3%)). Sirolimus was held prior to pregnancy in 2 patients; both these patients experienced a spontaneous pneumothorax in the first trimester and resumed sirolimus in the second trimester with no further pneumothoraces during the rest of the pregnancy. The median sirolimus dose during pregnancy was 1 (range 1-2) mg daily with a median trough level of 2.95 (range: 1 – 6.7) ng/ml. Ten pregnancies (83.3%) resulted in live births, 1 pregnancy was terminated due to molar pregnancy, and 1 pregnancy resulted in miscarriage. Spirometry and DLCO were available in 8 pregnancies and tended to be stable (Figure 1). None of the 10 pregnancies that resulted in live births reported any fetal health issues. Seven out of these 10 children (70%) were breastfed with continued sirolimus use. At the time of submission of this report, the median age of these children is 3.5 years (range: 1 – 6.5 years) with no reported adverse health outcomes from sirolimus exposure during pregnancy. Conclusions: The use of sirolimus during pregnancy in women with LAM appears to be safe for both mother and fetus and might help reduce the pregnancy associated risks of accelerated lung function decline and spontaneous pneumothoraces.
Proposed New MRI Scoring System of Rectosigmoid Endometriosis to Guide Operative Planning
Shahi, Maryam , Wang, Sherry S. , Li, Xiao , Çolak, Ceylan , Sheedy, Shannon P. , Bookwalter, Candice A., K, Feldman Myra, Khan, Zaraq , Johnson, Matthew P. , VanBuren, Wendaline M. , Takahashi, Hiroaki, Burnett, Tatnai L. , Jha, Priyanka , Feldman, Myra K,, Cope, Adela G.

Mayo Clinic

No container title available | May 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6336241/v1 Get It

Abstract Background: Rectosigmoid endometriosis (RSE) presents with a diverse array of MRI findings that impact surgical planning. No standardized reporting and data system has been established for RSE. Purpose: We propose a novel MRI scoring system designed to predict the likelihood of muscularis propria (MP) involvement in RSE, which would, in turn, influence surgical planning. Material and Methods: The records of patients with bowel endometriosis treated surgically from May 2018 to June 2022 were retrieved. Surgery was classified as partial thickness discoid, full thickness discoid, or segmental resection. Each pre-treatment MRI was scored based on the mutual agreement of two abdominal radiologists (reference score). The MRI score was defined as (1) score 0: no evidence of RSE, (2) score 1: minimal tethering involving the serosal surface without MP involvement, (3) score 2: intermediate soft tissue thickening involving the rectosigmoid colon with indeterminate MP involvement, or (4) score 3: definite mushroom cap sign or definite MP involvement. In the reader study, two radiologists independently scored each exam. The area under the curve (AUC) was evaluated for predicting the need for segmental or full thickness discoid resection. Results: The cohort consisted of 95 patients (median age: 36 years); 16, 14, 30, and 35 patients had MRI score 0, 1, 2, and 3, respectively. Patients with MRI scores 3 and 2 underwent partial thickness discoid (6% vs 50%), full thickness discoid (6% vs 17%), and segmental resection (89% vs 33%), respectively. All patients with MRI scores 1 or 0 either underwent partial thickness discoid resection or did not undergo rectosigmoid surgery. The AUCs were 92.2%, 84.5% and 93.9% for MRI scores of the reference, reader 1, and 2, respectively. Conclusion: Our MRI scoring system based on suspected depth of bowel invasion showed good diagnostic performance to predict the type of surgical intervention needed. Summary Statement This novel MRI scoring system for rectosigmoid endometriosis is a concise and qualitative scale based on suspected depth of bowel wall invasion to best guide operative planning.
Combined Heart and Liver Transplantation in the Failing Fontan: Systematic Review and Single-arm Meta-analysis
Vizentin, Vanessa Karlinski , Bulhões, Elísio , Ameduri, Rebecca , Johnson, Jonathan N. , Karlinski Vizentin, Vanessa, Ferreira Félix, Iuri, Antunes, Vânio , Félix, Iuri Ferreira , Mesquita, Cynthia Florêncio de

Mayo Clinic

Transplantation | May 5, 2025 | Volume: 109 | Issue: 11 | Pages: 1783-1791

10.1097/tp.0000000000005400 | PMID 40320589 Get It

Background. The Fontan procedure has transformed the management of congenital heart defects characterized by single ventricle physiology, yet it predisposes individuals to Fontan-associated liver disease. Combined heart and liver transplantation (CHLT) emerges as a therapeutic option, but evidence of its efficacy and safety remains limited. This study aimed to comprehensively evaluate CHLT in Fontan patients, focusing on patient characteristics, perioperative outcomes, and posttransplant morbidity and mortality. Methods. Following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, a systematic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was conducted. Studies meeting the intervention of CHLT in Fontan patients were included, and data were collected and synthesized using proportion meta-analysis techniques. Statistical analysis was carried out using R software. Results. Four studies met inclusion criteria, comprising 67 Fontan patients undergoing CHLT. All included studies were observational retrospective cohorts performed in the United States. The 1-y survival rate post-CHLT was 88% (95% confidence interval [CI], 70%-98%). Liver graft rejection rates were low, 4% (95% CI, 0%-22%), and no heart graft rejection greater than mild was reported. Postoperative complications included acute kidney injury 75% (95% CI, 50%-93%), temporary dialysis 27% (95% CI, 9%-51%), neurologic events 7% (95% CI, 0%-26%), infection 23% (95% CI, 3%-55%), and unplanned medical procedures 40% (95% CI, 23%-59%). Conclusions. CHLT in Fontan patients demonstrates promising survival rates, but graft rejection and postoperative complications pose challenges. The rate of renal complications is particularly notable and requires further evaluation. Future research should prioritize comparative different management strategies and long-term follow-up to refine protocols and optimize outcomes.
Programmed cell death protein 1 (PD-1) blockade regulates skeletal remodeling in a sex- and age-dependent manner
Joseph, Gwenyth J., Vecchi, Lawrence A., Kane, Jeremy, Durdan, Margaret , Hill, Paige, McAdoo, Ashtyn, Kell, David, Searcy, Madeline B, Nyman, Jeffry S. , Weivoda, Megan , Johnson, Rachelle W. , Weivoda, Megan M, Johnson, Rachelle W , Uppuganti, Sasidhar , Hill, Paige, Tanaka, Hidenori , Kell, David M. , Chen, Wei , Rosenthal, Eben L. , Harrison, David G.

Mayo Clinic

Journal of Bone and Mineral Research | May 3, 2025 | Volume: 40 | Issue: 8 | Pages: 950-964

10.1093/jbmr/zjaf055 | PMID 40318222 Get It

Abstract Immune checkpoint inhibitors (ICIs) block immunoregulatory receptor-ligand interactions and robustly increase survival of cancer patients but frequently result in immune-related adverse events (irAEs). While rheumatologic toxicities are commonly reported as irAEs, the effect of immune checkpoint blockade on the underlying mechanisms of ICI-induced fractures and bone loss is controversial, with reports of both positive and negative effects on bone mass in preclinical models. However, no previous reports have investigated the impact of ICIs on females or aged mice, or on fracture risk in either sex. We report that global deletion of programmed cell death protein 1 (PD-1) broadly results in bone loss in skeletally mature male and female PD-1−/− mice, with a sexually divergent phenotype in adolescent mice, decreased bone strength in adult males and young females, and expansion of multiple T cell subsets in the bone marrow. In a model of pharmacologic PD-1 blockade, administration of α-PD-1 reduced bone mass, expanded multiple T cell subsets in the bone marrow, and increased osteoclast activity and resorptive capacity. T cell deficient mice were resistant to osteoclast-mediated bone loss following α-PD-1 therapy, suggesting that T cells in the bone marrow are necessary for bone loss in the setting of ICI therapy. These findings may be leveraged to identify patients at greater fracture risk following ICI therapy due to enrichment of effector T cell populations in the bone marrow.
Genome‐wide association analysis identifies APOE as a mitophagy modifier in Lewy body disease
Hou, Xu , Fiesel, Fabienne C. , White, Launia J. , Quicksall, Zachary , Reddy, Joseph S. , Ross, Owen A. , Valentino, Rebecca R. , Ross, Owen A , Fiesel, Fabienne C , Hou, Xu , Heckman, Michael G. , Koga, Shunsuke , Soto‐Beasley, Alexandra I. , Watzlawik, Jens O. , Zhao, Jing , Johnson, Patrick W. , Brás, José , Guerreiro, Rita , Zhao, Na , Bu, Guojun , Dickson, Dennis W. , Springer, Wolfdieter

Mayo Clinic

Alzheimer's & Dementia | May 1, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.70198 | PMID 40309932 Get It

AbstractINTRODUCTIONPhosphorylated ubiquitin (p‐S65‐Ub) is generated during PINK1‐PRKN mitophagy as a specific marker of mitochondrial damage. Despite the widespread deposition of p‐S65‐Ub in aged and diseased human brain, the genetic contribution to its accumulation remains unclear.METHODSTo identify novel mitophagy regulators, we performed a genome‐wide association study using p‐S65‐Ub level as a quantitative trait in 1012 autopsy‐confirmed Lewy body disease (LBD) samples.RESULTSWe identified a significant genome‐wide association with p‐S65‐Ub for rs429358 (apolipoprotein E ε4 [APOE4]) and a suggestive association for rs6480922 (ZMIZ1). APOE4 was associated with higher p‐S65‐Ub levels and greater neuropathological burden. Functional validation in mouse and human induced pluripotent stem cell (iPSC) models confirmed APOE4‐mediated mitophagy alterations. Intriguingly, ZMIZ1 rs6480922 was associated with lower p‐S65‐Ub levels, reduced neuropathological load, and increased brain weight, indicating a potential protective role.DISCUSSIONOur findings underscore the importance of mitochondrial quality control in LBD pathogenesis and nominate regulators that may contribute to disease risk or resilience.Highlights p‐S65‐Ub levels were used as a quantitative marker of mitochondrial damage. A GWAS identified two genetic variants that modify mitophagy in LBD autopsy brain. APOE4 was associated with increased p‐S65‐Ub accumulation and neuropathology. APOE4 altered mitophagy via pathology‐dependent and pathology‐independent mechanisms. ZMIZ1 was linked to reduced p‐S65‐Ub and neuropathology indicative of protection.
Current State of Baseball Interval Throwing Programs: A Systematic Review of Content, Structure, and Variability of Published Throwing Programs
Iyer, Sanathan, Simon, Karissa N. , Cherny, Chad E., Johnson, Andrew , Zajac, John M., Christoffer, Daniel J., Hellem, Aaron R., Finck, Adam N., Langhans, Mark T. , Boos, Alexander M. , Johnson, Andrew J, Camp, Christopher L. , Iyer, Sanathan, Johnson, Andrew J., Johnson, Andrew

Mayo Clinic

Sports Health: A Multidisciplinary Approach | April 29, 2025 | Volume: 17 | Issue: 6 | Pages: 1214-1224

10.1177/19417381251333402 | PMID 40298098 Get It

Context: There is need for an up-to-date comprehensive review of baseball interval throwing programs in the literature. Objective: To (1) understand the origin and basis of interval throwing programs; (2) evaluate the content of programs in the peer-reviewed literature including target audience, initiation criteria, throwing specifics, arm care, and performance evaluation metrics; (3) classify these variables as well defined, ambiguous, or missing; and (4) analyze variability in key aspects including starting criteria, length, progression, and completion criteria. Data Sources: Medline, Embase, Cochrane Reviews, Web of Science, and Scopus Study Selection: The full text of studies, in English, had to be available. Included studies had to contain a complete interval throwing program designed for baseball players. Study Design: Systematic review. Level of Evidence: Level 4. Data Extraction: Initial screening was conducted based on article title and abstract. Full text of the remaining articles was evaluated for fulfillment of inclusion criteria. Results: Nine studies initially met inclusion criteria. The programs’ comprehensiveness was poor, with a mean Interval Throwing Program Checklist score of 20 (range 14-23) on a scale of 0 to 30. There were a variety of components, including progressive long toss, weighted ball, and throwing mechanics exercises. The programs identified had significant heterogeneity in duration, intensity, progression, and focus. Overall, there was a significant lack of attempts at validation or formal study of efficacy for published throwing programs. Conclusion: Current published interval throwing programs are mostly variations of an original program published many years ago and were based on principles of progressive loading with pain as sign of injury that should be monitored carefully. However, these programs have minimal clinical validation and objective measures to quantify their effectiveness. This work identifies several limitations in the current literature and can serve as a foundation for future development of evidence-based interval throwing programs.
Acute Megakaryoblastic Leukemia Masquerading as a Germ Cell Tumor
Olson, Lindsay M., Gurney, Mark E. , Li, Marissa , Yao, Yuan , Johnson, Tucker F. , Olteanu, Horatiu , Gangat, Naseema , Gurney, Mark , Johnson, Tucker, Li, Marissa M , Olson, Lindsay M.

Mayo Clinic

American Journal of Hematology | April 28, 2025 | Volume: 100 | Issue: 11 | Pages: 2099-2101

10.1002/ajh.27698 | PMID 40293222 Get It

Associations of Mid- and Late-Life Physical Activities With New-Onset Depression and Anxiety Among Older Adults
Syrjanen, Jeremy A. , Kremers, Walter K. , Barisch‐Fritz, Bettina , Krafft, Jelena , Johnson, DeJarra, Fields, Julie A. , Petersen, Ronald , Vassilaki, Maria , Geda, Yonas E., Krell-Roesch, Janina, Barisch-Fritz, Bettina, Wöll, Alexander , Kremers, Walter K , Krell‐Roesch, Janina , Johnson, DeJarra

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | April 28, 2025 | Volume: 38 | Issue: 1 | Pages: 76-83

10.1176/appi.neuropsych.20240255 | PMID 40289590 Get It

Abstract CT269: First-in-human trial in patients with metastatic colorectal cancer using CRISPR-engineered tumor infiltrating lymphocytes in which the intracellular immune checkpoint CISH is inhibited
Choudhry, Modassir, Folsom, Timothy D., Rathmann, Blaine, DeFeo, Anthony P. , Kim, Ji Hyun , Sumstad, Darin , Klebanoff, Christopher A. , Ladner, Katherine J., Sarkari, Akshat , McIvor, R. Scott , Rao, Madhuri , Ankeny, Jacob S. , Khalifa, Mahmoud A. , Chauhan, Anil , Dixit, Ajay , Weber, Daniel , Byrne‐Steele, Miranda, Henley, Tom , McKenna, David H. , Johnson, M. J. , Webber, Beau R. , Webber, Beau R , Lou, Emil , Starr, Timothy K. , Bell, Jason B , Slipek, Nicholas J. , Jin, Zhao-Hui , Murray, Thomas A. , Miller, Jeffrey S. , Jensen, Eric Hans , Spilseth, Benjamin , Provenzano, Paolo P. , Pan, Wenjing , Moriarity, Branden S.

Mayo Clinic

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: CT269-CT269

10.1158/1538-7445.am2025-ct269 Get It

Abstract Background: Given the dramatic rise in incidence of colorectal cancer in young adults, there remain limited treatment options effective in metastatic disease. Although T cell-based therapies have been successful in treating highly antigenic cancers, like melanoma and lung, they have not yet been shown to induce consistent and durable tumor regression in common epithelial malignancies, including metastatic colorectal cancer (mCRC). CISH (Cytokine inducible SH2 containing protein) is a novel intracellular checkpoint target demonstrating PD-L1 ligand independent mechanisms of enhanced anti-cancer activity. Given that CISH is not currently tractable via antibody or small molecule drug modalities, we employed CRISPR for precise inhibition of CISH in tumor infiltrating lymphocytes (TILs). Here, we provide the first clinical report of safety and anti-tumor activity of CISH edited TILs in 12 patients with metastatic gastrointestinal cancers (NCT04426669), including a clinical complete response (CR) in a young-adult patient with immunotherapy-refractory mCRC. Methods: Tumors were surgically resected for TIL harvest, followed by a rapid expansion protocol and CRISPR/Cas9 knockout (KO) CISH. CISH KO, neoantigen-reactive TILs were expanded, then infused following non-myeloablative lymphocyte depleting (LD) chemotherapy (cyclophosphamide & fludarabine) followed by high-dose IL-2. To establish mechanistic attribution of the CR, we used iR-RepSeq+ for serial analysis of the TCR immune repertoire. Results: Our CRISPR engineering led to KO of CISH in T cells with high-efficiency (>90%) without detectable off-target editing. We safely dosed patients at all five dose levels (range: 1.91e8 to 9.93e10 cells). No dose-limiting toxicities attributable to the CISH-KO TIL product were observed. Adverse events were consistent with established risks of LD chemotherapy, IL-2, or disease progression. A durable ongoing complete response (>21 months) was achieved in a patient with microsatellite instability-high (MSI-H) mCRC refractory to anti-PD1/CTLA-4 combination therapy. Conclusions: We provide the first clinical report of CISH checkpoint targeting via genetically modified T cell therapy, with complete response in a patient with mCRC. Persistence and expansion of unique TCR clonotypes detected in neoantigen responsive TIL was temporally consistent with spikes in CISH edited alleles detected by NGS assay; in the patient with CR, four of the clonotypes exhibiting prolonged persistence greater than one-year post-infusion exhibited significantly reduced or undetectable expression of CISH compared to the total infused TIL population. Given these findings, further investigation of CISH checkpoint inhibition, via gene and cell therapy, and next-generation small molecule drugging modalities, is underway. Citation Format: Emil Lou, Modassir S. Choudhry, Timothy K. Starr, Timothy Folsom, Jason Bell, Blaine Rathmann, Anthony P. DeFeo, Ji Hyun Kim, Nicholas Slipek, Zhaohui Jin, Darin Sumstad, Christopher A. Klebanoff, Katherine Ladner, Akshat Sarkari, R Scott McIvor, Thomas A. Murray, Jeffrey Miller, Madhuri Rao, Eric Jensen, Jacob Ankeny, Mahmoud A. Khalifa, Anil Chauhan, Benjamin Spilseth, Ajay Dixit, Paolo P. Provenzano, Wenjing Pan, Daniel Weber, Miranda Byrne-Steele, Tom Henley, David H. McKenna, Matthew J. Johnson, Beau R. Webber, Branden S. Moriarity. First-in-human trial in patients with metastatic colorectal cancer using CRISPR-engineered tumor infiltrating lymphocytes in which the intracellular immune checkpoint CISH is inhibited [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT269.